Last reviewed · How we verify
paracetamol-NSAID — Competitive Intelligence Brief
phase 3
Analgesic combination (paracetamol + NSAID)
Pain Management
Small molecule
Live · refreshed every 30 min
Target snapshot
paracetamol-NSAID (paracetamol-NSAID) — University of Monastir. This combination drug pairs paracetamol's direct analgesic and antipyretic effects with NSAID anti-inflammatory activity to provide enhanced pain relief and fever reduction.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| paracetamol-NSAID TARGET | paracetamol-NSAID | University of Monastir | phase 3 | Analgesic combination (paracetamol + NSAID) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Analgesic combination (paracetamol + NSAID) class)
- University of Monastir · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- paracetamol-NSAID CI watch — RSS
- paracetamol-NSAID CI watch — Atom
- paracetamol-NSAID CI watch — JSON
- paracetamol-NSAID alone — RSS
- Whole Analgesic combination (paracetamol + NSAID) class — RSS
Cite this brief
Drug Landscape (2026). paracetamol-NSAID — Competitive Intelligence Brief. https://druglandscape.com/ci/paracetamol-nsaid. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing